PhaseBio Pharmaceuticals, Inc.

PHAS · NASDAQ
Analyze with AI
6/30/2022
3/31/2022
12/31/2021
9/30/2021
Assets
Cash & Equivalents$7,804$18,688$41,800$56,357
Short-Term Investments$0$0$0$0
Receivables$0$0$0$0
Inventory$0$0$0$0
Other Curr. Assets$3,760$8,881$6,984$8,884
Total Curr. Assets$11,564$27,569$48,784$65,241
Property Plant & Equip (Net)$10,544$11,038$11,699$12,427
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$0$0$0$0
Tax Assets$0$0$0$0
Other NC Assets$58$57$57$57
Total NC Assets$10,602$11,095$11,756$12,484
Other Assets$0$0$0$0
Total Assets$22,166$38,664$60,540$77,725
Liabilities
Payables$6,320$6,778$12,570$8,521
Short-Term Debt$4,503$5,875$5,413$5,884
Tax Payable$0$0$0$0
Deferred Revenue$1,400$1,594$1,547$1,414
Other Curr. Liab.$12,456$7,441$8,353$5,638
Total Curr. Liab.$24,679$21,688$27,883$21,457
LT Debt$869$969$2,432$3,900
Deferred Rev, NC$7,443$7,458$7,622$7,913
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$106,573$110,944$115,637$94,784
Total NC Liab.$114,885$119,371$125,691$106,597
Other Liabilities$0$0$0$0
Cap. Leases$0$0$0$0
Total Liabilities$139,564$141,059$153,574$128,054
Equity
Pref Stock$0$0$0$0
Common Stock$50$49$48$48
Retained Earnings-$419,600-$402,935-$391,794-$348,684
AOCI$0$0$0$0
Other Equity$302,152$300,491$298,712$298,307
Total Equity-$117,398-$102,395-$93,034-$50,329
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$22,166$38,664$60,540$77,725
Net Debt-$2,432-$11,844-$33,955-$46,573